NCT01229254View on ClinicalTrials.gov

Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter

PHASE2CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

April 30, 2011

Conditions
Atrial FibrillationAtrial Flutter
Interventions
DRUG

Amiodarone

Patients on Amiodarone

DRUG

Betrixaban 60 mg

Betrixaban 60 mg once a day with food on Day 0 through Day 25

DRUG

Betrixaban 90 mg

Betrixaban 90 mg once a day with food on Day 0 through Day 25

DRUG

Betrixaban 30 mg

Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.

Sponsors
All Listed Sponsors
lead

Portola Pharmaceuticals

INDUSTRY

NCT01229254 - Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter | Biotech Hunter | Biotech Hunter